Prostate cancer is one of the most prevalent cancers in men and represents a severe burden on both patients and healthcare systems in western societies. To address the limitations of current risk stratification methods, the aim of this thesis was to identify novel biomarkers, such as RNA molecules that can discriminate PCa from non-cancerous conditions with high specificity and/or allow accurate prediction of disease outcome. Moreover, we aimed to advance next generation sequencing in clinical applications by addressing and simplifying some of the associated bioinformatics challenges.

Additional Metadata
Keywords prostate cancer, prostate carcinoma, biomarkers, PDE4D, lncRNA, long non-coding RNA, diagnosis, prognosis, aggressive disease, microarray, RNA-seq, next generation sequencing, bioinformatics
Promotor G.W. Jenster (Guido) , P. Beyerlein (Peter)
Publisher Erasmus University Rotterdam
Sponsor The research in this thesis was financially supported by the Center for Translational Molecular Medicine (CTMM) PCMM (grant 03O-203) and NGS ProToCol projects (03O-402). The printing of this thesis was financially supported by the Stichting Wetenschappelijk Onderzoek Prostaatkanker, Rotterdam (SWOP).
Persistent URL hdl.handle.net/1765/94115
Citation
Böttcher, R. (2016, November 22). Identification of Novel Prostate Cancer Biomarkers Using High-throughput Technologies. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/94115